Join

Compare · MO vs MTCR

MO vs MTCR

Side-by-side comparison of Altria Group Inc. (MO) and Metacrine Inc. (MTCR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MO and MTCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • MO is the larger of the two at $116.21B, about 5338.4x MTCR ($21.8M).
  • MO has hit the wire 6 times in the past 4 weeks while MTCR has been quiet.
  • MO has more recent analyst coverage (19 ratings vs 4 for MTCR).
MetricMOMTCR
Company
Altria Group Inc.
Metacrine Inc.
Price
$69.61-3.23%
$0.49-0.50%
Market cap
$116.21B
$21.8M
1M return
-3.86%
-
1Y return
+18.34%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
6
0
Recent ratings
19
4
MO

Altria Group Inc.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

MTCR

Metacrine Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Latest MO

Latest MTCR